Bevacizumab as a surgery-sparing agent for spinal ependymoma in patients with neurofibromatosis type II: Systematic review and case

Authors

M Harrison Snyder, Department of Neurological Surgery, University of Virginia Health System, Charlottesville, VA, USA.
Leonel Ampie, Department of Neurological Surgery, University of Virginia Health System, Charlottesville, VA, USA; Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA. Electronic address: la2de@virginia.edu.
Joseph D. DiDomenico, Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.Follow
Ashok R. Asthagiri, Department of Neurological Surgery, University of Virginia Health System, Charlottesville, VA, USA.

Document Type

Article

Abstract

Neurofibromatosis type 2 (NF2) is a rare, hereditary tumor syndrome, often requiring repeated surgeries for multiple lesions with significant cumulative morbidity. As such, non-operative management should be considered when possible for this patient population. The aim of this study is to provide a systematic review of the literature regarding this treatment strategy. A descriptive case of a patient in whom bevacizumab treatments enabled over 15 years of surgical postponement for a symptomatic spinal cord ependymoma is also provided. Evidence suggests that bevacizumab is a reasonable surgery-deferring option for cystic lesions, and it may be especially useful in NF2 patients to reduce cumulative morbidity.

Medical Subject Headings

Adult; Antineoplastic Agents, Immunological (therapeutic use); Bevacizumab (therapeutic use); Conservative Treatment (methods, trends); Ependymoma (complications, diagnostic imaging, drug therapy); Female; Humans; Neurofibromatosis 2 (complications, diagnostic imaging, drug therapy); Spinal Cord Neoplasms (complications, diagnostic imaging, drug therapy)

Publication Date

4-1-2021

Publication Title

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia

E-ISSN

1532-2653

Volume

86

First Page

79

Last Page

84

PubMed ID

33775351

Digital Object Identifier (DOI)

10.1016/j.jocn.2021.01.010

Recommended Citation

Snyder, M Harrison; Ampie, Leonel; DiDomenico, Joseph D.; and Asthagiri, Ashok R., "Bevacizumab as a surgery-sparing agent for spinal ependymoma in patients with neurofibromatosis type II: Systematic review and case" (2021). Neurosurgery. 2165.
https://scholar.barrowneuro.org/neurosurgery/2165